Abbisko Cayman Limited

Equities

2256

KYG0028A1085

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:28 2024-05-20 EDT			5-day change	1st Jan Change
3.69 ^HKD	-1.34%		+6.96%	+1.10%

05-09	Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination with Shanghai Allist's Furmonertinib	MT
04-29	Abbisko Cayman Limited Appoints Yu Hongping as Joint Company Secretaries	CI

Abbisko Cayman Limited Announces Resignation of Dr. XIA Gavin Guoyao as Non-Executive Director

June 19, 2023 at 05:12 am

The board of director of Abbisko Cayman Limited announced that, on June 19, 2023, Dr. XIA Gavin Guoyao tendered his resignation as a non-executive Director with effect from June 19, 2023 due to his other commitments which require more of his dedication.

Latest news about Abbisko Cayman Limited

Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination with Shanghai Allist's Furmonertinib	05-08	MT
Abbisko Cayman Limited Appoints Yu Hongping as Joint Company Secretaries	04-29	CI
Abbisko Cayman's Liver Cancer Drug Gets US FDA Orphan Drug Designation	04-25	MT
Abbisko Cayman Limited Voluntary Announcement FGFR4 Inhibitor Irpagratinib Granted Odd by FDA	04-24	CI
Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary	04-24	CI
Abbisko Cayman's Unit Presents Pre-Clinical Study of Liver Cancer Drug at AACR Annual Meeting	04-09	MT
Abbisko Cayman Completes Patient Enrollment for Phase 3 Trial of Joint Tumor Treatment	04-08	MT
Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib	04-08	CI
Abbisko Cayman's Attributable Loss Narrows as Revenue, Other Gains Rise	03-14	MT
Abbisko Cayman to Buy Back, Cancel Up to HK$100 Million Shares	03-13	MT
Abbisko Cayman Limited commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.	03-12	CI
Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Abbisko Cayman Completes Dosing for Phase 1 Trials for Lung Cancer Treatment	02-22	MT
Abbisko Cayman Receives $70 Million Upfront Payment for Licensing of Tumor Treatment	02-05	MT
Abbisko Cayman Trustee Buys 6.1 Million Shares Under Restricted Share Scheme	02-02	MT
European Medicines Agency Grants Orphan Drug Designation to Abbisko's Tumor Drug	01-09	MT
Abbisko Cayman Doses First Participant in Phase 1 Trial for Anti-Tumor Treatment; Shares Fall 3%	01-03	MT
Abbisko Therapeutics Co., Ltd. Completes the First Patient Dose in the Clinical Trial for Its Next-Generation CD73 Inhibitor ABSK051	01-02	CI
Abbisko Cayman Unit Gets US FDA Fast-Track Status for Tenosynovial Giant Cell Tumor Treatment	12-13	MT
Abbisko Therapeutics Announces U.S. FDA Grants Fast Track Designation for CSF-1R Inhibitor Pimicotinib	12-13	CI
Abbisko Cayman Doses First Patient in Phase 2 Trial for Pancreatic Cancer Treatment	11-27	MT
Abbisko Therapeutics Completed the First Patient Dose in the Phase II Advanced Pancreatic Cancer Trial of CSF-1R Inhibitor Pimicotinib in China	11-27	CI
China Approves Abbisko Cayman Subsidiary's Clinical Trial for Tumor Drug	11-09	MT
Abbisko Therapeutics Co., Ltd. Obtains the Clinical Trial Approval from NMPA for its Next-Generation Small Molecule CD73 Inhibitor ABSK051	11-08	CI
US FDA Green Lights Abbisko Subsidiary's Phase 1 Study for Anti-Tumor Drug	11-07	MT

Chart Abbisko Cayman Limited

Duration

Period

More charts

Company Profile

Abbisko Cayman Ltd is a China-based clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Companyâs products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

Sector

Biotechnology & Medical Research

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Abbisko Cayman Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.423 CNY

Average target price

7.572 CNY

Spread / Average Target

+121.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ABBISKO CAYMAN LIMITED	+1.10%	311M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-12.38%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.35%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.42B

Bio Therapeutic Drugs